



Hematology

438 teamwork

| Chronic Leukemia

Color index:

Red: Important

Gray: notes


Blue: extra

 [*Editing file*](#)







Chronic leukaemia

- Heterogeneous group of hematopoietic neoplasms.
- It is uncontrolled proliferation and decreased apoptotic activity with variable degrees of differentiation.
- Composed of relatively **mature cells**.
- Indolent. (If untreated, the course is in months or years).
- Occurs mainly in **adults**
- Types : MPN , MDS , MPN/MDS.




Main types of leukemia

		Acute	Chronic
Lymphoid	ALL		LPN(CLL) 
Myeloid	AML		MPN/MDS (CML) 
Mixed	Acute Biphenotypic		
Non	Acute		

Myeloid proliferative neoplasms (MPN)

- Malignant proliferation of myeloid cells (maturing cells) which are mainly **granulocytes**, in blood and bone marrow.
- Slow onset and long course.
- Occurs mainly in **adults**.


Features:



Chronic myeloid leukemia (CML)

- Stem cell MPN.
- Predominant **proliferation of granulocytic cells**.
- Consistently associated with the **BCR-ABL1 fusion gene**, located in the **Philadelphia (Ph) chromosome** which results from **t(9;22)**.
- If the mutation happened at (myeloblast) it is AL, otherwise it will be CL especially neutrophils.

Pathogenesis:



01

t(9;22) happened

02

BCR-ABL1

02



Increase Tyrosine Kinase

03

Activation of signal transduction pathways

04

Uncontrolled proliferation



Clinical presentation of CML

01

Asymptomatic presentation (20-40%)

02

Abdominal discomfort due to splenomegaly

03

Routine CBC : **marked leukocytosis** (increase in WBCs)

04

Splenomegaly (Massive)


05

Common symptoms :
Fatigue ,weight loss or
night sweating



Neutrophil Alkaline Phosphatase (NAP) score:


Cytochemical stain that estimate the amount of alkaline phosphatase enzyme in neutrophils .



Treatment of CML

If no response

Stem cell transplantation



Targeted therapy

Tyrosine kinase inhibitors

Imatinib , Gleevec


Excellent response
(5 years overall survival \geq 90%)

CML phases

01

Chronic phase:


- Leukocytosis ($12-1000 \times 10^9/L$)
- Mainly neutrophils & myelocytes
- Blasts $\leq 10\%$, Basophils $\leq 20\%$
- Stable course (years)



02

Accelerated phase:


- Increasing counts
- 10-19% blasts (basophils $\geq 20\%$)
- Unstable course (months)



03

Blastic phase:

- $\geq 20\%$ blasts = Acute Leukemia
- 80% AML & 20% ALL
- (course: Weeks)



Myelodysplastic Syndromes (MDS)




Group of myeloid neoplasms characterized by:

- Peripheral cytopenia (**Low HB** ± **Low WBC** & **Low PLT**).
- **Dysplasia (abnormal morphology)**.
- **Ineffective hematopoiesis (hypercellular marrow)**.
- Progression to AML (preleukaemic disease). just like CML
- Enhanced apoptosis.

death happens within the BM ie; premature death of RBC, thrombocytes, granulocytes And monocytes.

Blood: Pancytopenia with dysplasia.

BM: Hypercellular with dysplasia.



Subtypes according to:

Blast count, degree of dysplasia and genetics.

Treatment

Supportive ± chemotherapy.

01

02

03


Genetic Abnormalities

Mainly in -5 and -7

↑ Proliferation + ↑ Apoptosis = Ineffective Hematopoiesis

Differential Diagnosis

	CML	Leukemoid
Age	Adult	Any age
WBC count	High	High but < 100,000
Differential	Mainly myelocytes & segmented	Mainly bands
Morphology	Hypogranular	Toxic
Splenomegaly	+	±
NAP score	Low	High
BCR/ABL	+ve	-ve
Onset	Chronic	Acute



- 1- **Chronic myelomonocytic leukemia:** (**monocytosis**, BCR-ABL -ve). N.B chronic myeloid leukemia was mainly granulocytes “neutrophils”
- 2- **Leukemoid reaction:** Leukocytosis due to physiological response to stress or infection

Chronic Myelomonocytic Leukemia (CMML)

Clonal hematopoietic malignancy characterized by:

- Proliferation of monocytes.
- Proliferation of neutrophils.
- Negative for Philadelphia Chromosome.
- Blast must be less than 20%.

MDS Features

Dysplasia & enhanced apoptosis.

MPN Features

Marked proliferation.

MDS/MPN


The reason why it's called by these two diseases:

Course

Aggressive course
(survival rate around
2.5 years).

Treatment

Chemotherapy ± Stem
Cell Transplant (SCT)



1-22 years old male come to ER with splenomegaly; examination show increasing in WBCs and high Uric acid. Microscopic results show hypercellular bone marrow. What's your diagnosis?

- A. MPN
- B. CML
- C. MDS
- D. CMML

2- CML associated with

- A. BCR-ABL2 fusion gene in Ph chromosome which result from t(9;22)
- B. BCR-ABL1 fusion gene in Ph chromosome which result from t(9;22)
- C. BCR-ABL1 fusion gene in Ph chromosome which result from t(8;14)
- D. BCR-ABL1 fusion gene in Ph chromosome which result from t(9;21)

3- The most important characteristic for CMML

- A. Basophil proliferation
- B. Monocyte proliferation
- C. B lymphocyte proliferation
- D. Eosinophil proliferation

4- The most important characteristic for MDS (from dr.notes)

- A. HyperCellular bone marrow
- B. HypoCellular bone marrow
- C. Peripheral blood cyropenia
- D. A & C

THANKS


| TEAM LEADERS

| Abdulaziz Alghamdi

 | *Elaf Almusahel*

| TEAM MEMBERS

-  *Amirah Alzahrani*
- *Deema Almaziad*
-  *Jude Alotaibi*
- *Njoud Almutairi*
-  *Nouf Albraikan*
- *Noura Almazrou*
- *Razan Alzohaifi*
-  *Rema Almutawa*
- *Renad Alhaqbani*
- *Renad Almutawa*
-  *Taif Alotaibi*
- *Wejdan Alnufaie*

- *Abdullah Alghamdi*
-  *Hashem Bassam*
- *Mashal Abaalkhail*
- *Moath Aljehani*
- *Mohammed Alasmari*
- *Mohammed H.Alshehri*
- *Mohammed Alkamees*
- *Mohammed Alshalan*
- *Naif Alsolais*
- *Raed Alojayri*
- *Saud Bin Queid*

   = Done by

 = Editor *مستفي*

 = Note taker

 = Textbooks note taker